Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

10 output Results for «Ulcerative colitis»

ArticleOpen access202512citation· Semantic Scholar

The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study

Frontiers in Pharmacology · vol. 16 · 1507009-1507009

Background: Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and clinical settings have looked into the several metabolic pathways via which metformin protects against UC. Aim: To assess efficacy of metformin as adjunctive therapy in patients with mild to moderate UC. Methods: This clinical research was double-blinded, randomized, controlled, and involved 60 patients with mild to moderate UC. The participants were randomly assigned to one of two groups (n = 30). The control group was given 1 g of mesalamine three times a day (t.i.d.) for a period of 6 months (mesalamine group). The metformin group was given 500 mg of metformin twice daily and 1 g of mesalamine t. i.d. For a period of 6 months. Patients with UC were assessed by a gastroenterologist using the disease activity index (DAI) both at the beginning of treatment and 6 months thereafter. To evaluate the drug's biological efficacy, measurements of fecal calprotectin, serum C-reactive protein (CRP), interleukin 10 (IL-10), and nitric oxide (NO) were taken both before and after treatment. Study outcomes: Decrease in DAI and change in the level of measured serum and fecal markers. Results: = 0.04) when compared to the mesalamine group. There was a significant direct correlation between DAI and calprotectin (p < 0.0001, r = 0.551), and between DAI and CRP (p < 0.0001, r = 0.794). There was a significant negative correlation between DAI and IL-10 (p = 0.0003, r = 0.371). Conclusion: Metformin may be an effective adjunct drug in management of patients with mild to moderate UC by decreasing DAI and other inflammatory markers that were involved in the pathogenesis of UC. Clinical Trial Registration: identifier NCT05553704.

metforminulcerative colitis5-aminosalicylic acidadjunctive therapy
ArticleOpen access20253citation· Semantic Scholar

Colo‐Protective Effects of Pentoxifylline Alone or in Combination With Mesalamine in Colitis Through Sphingosine Kinase 1/Sphingosine 1 Phosphate, and Zonula Occuldin 1 Pathways: New Molecular Approach

Pharmacology Research & Perspectives · vol. 13 (3) · e70115-e70115

Multiple signaling pathways have been implicated in the pathogenesis of ulcerative colitis (UC), including Sphingosine Kinase 1 (SPHK)/Sphingosine-1-Phosphate (S1P), AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/NLR family pyrin domain-containing 3 (NLRP3), zonula occludens-1 (ZO-1), and signal transducer and activator of transcription 3 (STAT3). We aimed to investigate the Colo protective and anti-ulcerative effects of pentoxifylline (PTX) in a rat model of UC. Colitis was induced by intracolonic administration of 2 mL of 3% (v/v) acetic acid (AA). Thirty-five rats were randomly assigned to five groups (n = 7 each): normal control, colitis, mesalamine, PTX, and a combination of PTX plus mesalamine. Disease activity was assessed using the disease activity index, colon weight and length measurements, histological examination, and immunohistochemical detection of caspase-3. Colonic tissue homogenates were analyzed for interleukin-6 (IL-6), S1P, SPHK, mTOR, heme oxygenase-1 (HO-1), nuclear factor erythroid 2-related factor 2 (Nrf2), AMPK, and STAT3 levels. Gene expression of ZO-1 and NLRP3 was also evaluated. Intracolonic AA induced marked functional, biochemical, and inflammatory damage to colonic tissue. Treatment with PTX, mesalamine, or their combination significantly attenuated these effects. Specifically, all treatments reduced levels of IL-6, S1P, SPHK, mTOR, STAT3, NLRP3, and caspase-3, while increasing levels of ZO-1, HO-1, Nrf2, and AMPK. The combination treatment group exhibited near-complete restoration of normal colonic architecture, characterized by intact crypt morphology and minimal fibrosis in the lamina propria. PTX attenuated inflammation, apoptosis, and oxidative stress in colitis, supporting its potential as an adjuvant therapy in UC management.

pentoxifylline5-aminosalicylic acidulcerative colitissphingosine kinase 1
ArticleOpen access202416citation· Semantic Scholar

Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study

Drug Design Development and Therapy · vol. Volume 18 · 5239-5253

Background: Ulcerative colitis (UC) is an idiopathic chronic inflammation of colonic and rectal mucosa. The peroxisome proliferator-activated receptor α (PPARα) has been identified as having protective effects in UC. Aim: The study aimed to investigate the efficacy of fenofibrate, a PPARα agonist, in UC. Methods: A total of 70 patients with mild to moderate UC were allocated randomly and assigned to two groups (n = 35 each) from Gastroenterology Department, Faculty of Medicine, Menoufia University. The mesalamine group received a placebo along with 1 g of mesalamine three times daily, while the fenofibrate group received 1 g of mesalamine three times and fenofibrate 160 mg once daily. The study duration was for six months. A gastroenterologist assessed patients by non-invasive Partial Mayo Score (PMS) and the Inflammatory Bowel Disease Questionnaire (IBDQ) to evaluate clinical response and remission. The serum levels of silent information regulator 1 (SIRT1), NOD-like receptor protein 3 (NLRP3), and adenosine monophosphate activated protein kinase (AMPK), as well as fecal calprotectin levels were examined to determine the biological effect of fenofibrate. Results: After treatment, the fenofibrate group showed statistically significant reductions in PMS ( p = 0.044) and improved digestive domain of IBDQ ( p = 0.023). Additionally, there were significant decreases in serum NLRP3 ( p = 0.041) and fecal calprotectin ( p = 0.035), along with significant increases in SIRT1 ( p = 0.002) and AMPK ( p = 0.0003). The fenofibrate group also had higher response and remission rates compared to the mesalamine group. Conclusion: Fenofibrate may be a promising adjunct for improving clinical outcomes, quality of life, and modulating inflammation in mild to moderate patients with UC. Trial Registration Identifier: NCT05781698. Keywords: Ulcerative colitis, Fenofibrate, Mesalamine, NLRP3/AMPK, PPARα

ulcerative colitisfenofibrate5-aminosalicylic acidPPARα agonist
ReviewOpen access20239citation· Semantic Scholar

Urolithiasis in patients with inflammatory bowel disease: A systematic review and meta-analysis of 13,339,065 individuals

Medicine · vol. 102 (24) · e33938-e33938

BACKGROUND: This study aimed to summarize the current literature regarding the prevalence of renal stones in patients with inflammatory bowel disease (IBD). Moreover, we aimed to evaluate the risk factors of urolithiasis in patients with IBD and the difference between patients with IBD and healthy controls in terms of urinary profile. METHODS: On February 23, 2022, a computerized search was conducted on PubMed, OVID via MEDLINE, Web of Science, and Scopus using relevant keywords. Three independent reviewers performed 2-stage screening and data extraction. The National Institutes of Health tools were employed for quality assessment. Review Manager 5.4 software was used to calculate the mean difference (MD) between IBD patients and non-IBD in terms of urine profile using the Inverse-variance model and to estimate the odds ratio of reported risk factors for renal stones with the Generic Inverse-Variance model. RESULTS: Thirty-two articles (n = 13,339,065 patients) were included. The overall prevalence of renal stones in patients with IBD was 6.3%, 95% Confidence interval (4.8%-8.3%). The prevalence of urolithiasis was more common in Chron's disease vs Ulcerative colitis (7.9% vs 5.6%) and in old studies (1964-2009) than in more recent studies (2010-2022) (7.3% vs 5.2%), respectively. Compared to non-IBD patients, patients with IBD were associated with significantly lower urine volume (MD = -518.84 mL/day, P < .00001), calcium 24-hour urine (MD = -28.46 mg/day, P < .0001), citrate 24-hour urine (MD = -144.35 mg/day, P < .00001), sodium 24-hour urine (MD = -23.72 mg/day, P = .04), and magnesium 24-hour urine (MD = -33.25 mg/day, P < .00001). CONCLUSION: The overall prevalence of renal stones in patients with IBD was comparable to the general population. Patients with Chron's disease were associated with a higher prevalence of urolithiasis compared to Ulcerative colitis. Drugs that induce renal calculi should be stopped in high-risk patients.

urolithiasisinflammatory bowel diseasekidney stonesCrohn's disease
ArticleOpen access20222citation· Semantic Scholar

Prevalence and knowledge about inflammatory bowel diseases in Saudi Society

International Research Journal of Public and Environmental Health · vol. 9 (2) · 35-42

Inflammatory bowel diseases (IBD) are autoimmune illnesses that include Crohn's disease (CD) and ulcerative colitis (UC).The study's goal is to investigate the prevalence and awareness of both forms of IBD in the Saudi adult population.In July 2017, a cross-sectional research of 2,984 Saudis over the age of 18 was conducted.A self-administered questionnaire was used to examine the prevalence and knowledge of respondents.A scale of eight questions was utilised to measure general knowledge about IBD, with three separate categories: low, moderate, and high.There were 2,140 females (71.7 percent) and 844 men among the 2,984 Saudi participants.Participants with Crohn's disease (CD) and Ulcerative Colitis (UC) made up (1.9%) and (8.3%) of this group, respectively.The survey included all five areas of the Kingdom of Saudi Arabia: eastern (32.5 %), western (21.6 %), central (18.3 percent), northern (17.6 %), and southern (10.1 percent ).The survey's findings established the prevalence of IBD as well as the degree of understanding about it.The use of social media was critical in increasing public awareness about IBD.These statistics could aid in better understanding the burden of IBD in Saudi Arabia, as well as in identifying the problem and its treatment.

inflammatory bowel diseaseCrohn's diseaseulcerative colitisIBD prevalence
ArticleClosed2021

Anti‐inflammatory Effect of Betulin in Acetic Acid Induced Ulcerative Colitis: Effect on TLR4/NF‐kB

The FASEB Journal · vol. 35 (S1)

Background Ulcerative colitis (UC) is a common inflammatory bowel disease. The importance of experimental models for investigating the pathogenic mechanisms and assessment of potential therapeutic agents for UC is well established. Betulin is a natural triterpene compound that has been reported to exert wide spectrum of pharmacological and biological activities. Aim of the work The present study aims to evaluate the potential therapeutic effect of betulin against acetic acid (AA)‐induced UC in rats. Material and methods Thirty adult Sprague Dawley rats were randomly assigned into three groups: normal control, UC and UC+betulin (8 mg/kg). UC was induced by intracolonic instillation of AA (3% v/v) in 0.9% saline in all study groups except for the normal group. Four days post instillation of AA, UC+betulin group was treated by intraperitoneal administration of betulin once daily for 14 consecutive days. Results Results showed that betulin attenuated AA‐induced UC as evident by reduced macroscopic scores, decreased serum C reactive protein (CRP) titer and lactate dehydrogenase (LDH) activity and attenuated histopathological hallmarks including mucosal necrosis, haemorrhage, congestion and inflammatory cells infiltration. Moreover, betulin treatment dampened colonic inflammatory status via downregulation of toll like receptor‐4 (TLR4)/Nuclear factor‐κB NF‐kB axis accompanied by reduction of colonic inflammatory cytokines tumor necrosis factor‐α (TNF‐α) and Interleukin‐6 (IL‐6) as well as CD68 immunostaining. Additionally, betulin administration suppressed signs of apoptosis as shown by reduced caspase‐3 and caspase‐8 immunostaining compared with UC group. Conclusion Our findings demonstrate a novel therapeutic effect of betulin against UC via suppression of TLR4/NF‐κB signalling.

betulinulcerative colitisacetic acid-induced colitisTLR4/NF-κB signaling
ArticleClosed201513citation

Protective effect of Agave americana Linn. leaf extract in acetic acid-induced ulcerative colitis in rats

AYU (An International Quarterly Journal of Research in Ayurveda) · vol. 36 (1) · 101-101

INTRODUCTION: Natural plants always provide core compounds for new drug development. In the present life and food style, inflammatory bowel disease has become common and needs a lead compound for its drug development. AIM: To evaluate the effect of Agave americana Linn. leaf extract in acetic acid-induced ulcerative colitis in rats based on its traditional anti-inflammatory use. MATERIALS AND METHODS: Male Wistar rats were pretreated with A. americana leaf extract in the dose of 200 and 400 mg/kg p.o. daily for 7 days. On 8(th) day, 2 ml of 4% v/v acetic acid in saline was instilled into rats' rectum. Prednisolone was used as standard drug and it was administered on the day of acetic acid instillation and continued for 3 days. Extract treatment was continued till 11(th) day. Body weight, ulcer score, colonic muscle contraction, antioxidant activity and histopathology were studied. Statistical analysis was performed using Parametric one-way analysis of variance followed by Tukey's posttest. RESULTS: A. americana have retained total body weight significantly (P < 0.01) and decreased colon weight/length ratio. Extract have shown a significant decrease (P < 0.001) in ulcer scores, myeloperoxidase, lipid peroxidase activity. Further, extract have shown significant improvement in colonic muscle contraction, histopathology of colon etc., which is comparable with standard drug. CONCLUSION: A. americana possess protective effect against acetic acid-induced colitis in rats.

Agave americanaleaf extractulcerative colitisacetic acid-induced colitis